Use of goserelin in the treatment of breast cancerRODY, Achim; LOIBL, Sibylle; VON MINCKWITZ, Gunter et al.Expert review of anticancer therapy. 2005, Vol 5, Num 4, pp 591-604, issn 1473-7140, 14 p.Article

Breast cancer in pregnancyAMANT, Frederic; LOIBL, Sibylle; NEVEN, Patrick et al.Lancet (British edition). 2012, Vol 379, Num 9815, pp 570-579, issn 0140-6736, 10 p.Article

Neoadjuvant breast cancer therapy : the German experienceVON MINCKWITZ, Gunter; LOIBL, Sibylle; KAUFMANN, Manfred et al.European journal of cancer. Supplement (1990). 2008, Vol 6, Num 2, pp 4-9, issn 1359-6349, 6 p.Conference Paper

EGF-R and Her2/neu overexpressing tumors: independent collectives for treatment of breast cancer by specific monoclonal antibody-therapySOLBACH, Christine; ROLLER, Marc; BUDISCHEWSKI, Kai et al.Journal of cancer research and clinical oncology. 2003, Vol 129, Num 4, pp 250-251, issn 0171-5216, 2 p.Article

Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer : RiTa trialLOIBL, Sibylle; MURMANN, Caroline; SCHWEDLER, Katrin et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 5, pp 953-958, issn 0344-5704, 6 p.Article

Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)AZIM, Hatem A; METZGER-FILHO, Otto; DE AZAMBUJA, Evandro et al.Breast cancer research and treatment. 2012, Vol 133, Num 1, pp 387-391, issn 0167-6806, 5 p.Article

Anti-cancer immune response mechanisms in neoadjuvant and targeted therapyDENKERT, Carsten; DARB-ESFAHANI, Silvia; LOIBL, Sibylle et al.Seminars in immunopathology (Print). 2011, Vol 33, Num 4, pp 341-351, issn 1863-2297, 11 p.Article

Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)VON MINCKWITZ, Gunter; DARB-ESFAHANI, Silvia; CLEMENS, Michael R et al.Breast cancer research and treatment. 2012, Vol 132, Num 3, pp 863-870, issn 0167-6806, 8 p.Article

Effect of Luteinizing Hormone-Releasing Hormone Agonist on Ovarian Function After Modern Adjuvant Breast Cancer Chemotherapy: The GBG 37 ZORO StudyGERBER, Bernd; VON MINCKWITZ, Gunter; FEHM, Tanja et al.Journal of clinical oncology. 2011, Vol 29, Num 17, pp 2334-2341, issn 0732-183X, 8 p.Article

Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer ProgressionHILVO, Mika; DENKERT, Carsten; BERG, Emilia et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 9, pp 3236-3245, issn 0008-5472, 10 p.Article

Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: Results of a randomised trial (GABG-IV E-93) - The German Adjuvant Breast Cancer GroupEIERMANN, Wolfgang; GRAF, Erika; KAUFMANN, Manfred et al.European journal of cancer (1990). 2010, Vol 46, Num 1, pp 84-94, issn 0959-8049, 11 p.Article

The role of early expression of inducible nitric oxide synthase in human breast cancerLOIBL, Sibylle; BUCK, Angela; STRANK, Cornelia et al.European journal of cancer (1990). 2005, Vol 41, Num 2, pp 265-271, issn 0959-8049, 7 p.Article

Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumorsCHAN, Arlene; VERMA, Shailendra; LOIBL, Sibylle et al.Critical reviews in oncology/hematology. 2012, Vol 81, Num 2, pp 136-150, issn 1040-8428, 15 p.Article

Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cellsSPÄNKUCH-SCHMITT, Birgit; WOLF, Georg; SOLBACH, Christine et al.Oncogene (Basingstoke). 2002, Vol 21, Num 20, pp 3162-3171, issn 0950-9232Article

Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patientsHILVO, Mika; GADE, Stephan; ORESIC, Matej et al.International journal of cancer (Print). 2014, Vol 134, Num 7, pp 1725-1733, issn 0020-7136, 9 p.Article

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab ― Results of the randomised GeparQuinto study (GBG 44)HUOBER, Jens; FASCHING, Peter A; GERBER, Bernd et al.European journal of cancer (1990). 2013, Vol 49, Num 10, pp 2284-2293, issn 0959-8049, 10 p.Article

Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancerRUCKHÄBERLE, Eugen; KARN, Thomas; NEKLJUDOVA, Valentina et al.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 10, pp 1681-1689, issn 0171-5216, 9 p.Article

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast CancerVON MINCKWITZ, Gunter; EIDTMANN, Holger; SOLBACH, Christine et al.The New England journal of medicine. 2012, Vol 366, Num 4, pp 299-309, issn 0028-4793, 11 p.Article

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trialsVON MINCKWITZ, Gunter; UNTCH, Michael; MEHTA, Keyur et al.Breast cancer research and treatment. 2011, Vol 125, Num 1, pp 145-156, issn 0167-6806, 12 p.Article

Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopyLOIBL, Sibylle; VON MINCKWITZ, Gunter; WEBER, Sonja et al.Cancer. 2002, Vol 95, Num 6, pp 1191-1198, issn 0008-543XArticle

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisCORTAZAR, Patricia; LIJUN ZHANG; SWAIN, Sandra M et al.Lancet (British edition). 2014, Vol 384, Num 9938, pp 164-172, issn 0140-6736, 9 p.Article

Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR studyMAASS, Nicolai; HARBECK, Nadia; WAGNER, Steffen et al.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 12, pp 2047-2056, issn 0171-5216, 10 p.Article

Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast CancerVON MINCKWITZ, Gunter; SCHMITT, Wolfgang D; HILFRICH, Jörn et al.Clinical cancer research (Print). 2013, Vol 19, Num 16, pp 4521-4531, issn 1078-0432, 11 p.Article

Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study GroupLÜCK, Hans-Joachim; DU BOIS, Andreas; RICHTER, Barbara et al.Breast cancer research and treatment. 2013, Vol 139, Num 3, pp 779-787, issn 0167-6806, 9 p.Conference Paper

Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapyLOIBL, Sibylle; MÜLLER, Berit Maria; KULMER, Uwe et al.Breast cancer research and treatment. 2011, Vol 130, Num 2, pp 477-487, issn 0167-6806, 11 p.Article